T1	PROC 46 65	Estudio de Fase III
#1	AnnotatorNotes T1	C0282461; Phase 3 Clinical Trials; Research Activity
T2	CHEM 107 118	ruxolitinib
#2	AnnotatorNotes T2	C2931926; ruxolitinib; Organic Chemical · Pharmacologic Substance
T3	DISO 136 149	mielofibrosis
#3	AnnotatorNotes T3	C0026987; Myelofibrosis; Neoplastic Process
T4	PROC 224 309	Estudio de Fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico
T5	PROC 314 347	investiga la eficacia y seguridad
T6	CHEM 351 362	ruxolitinib
#4	AnnotatorNotes T6	C2931926; ruxolitinib; Organic Chemical · Pharmacologic Substance
T7	DISO 380 393	mielofibrosis
#5	AnnotatorNotes T7	C0026987; Myelofibrosis; Neoplastic Process
T8	DISO 468 481	Mielofibrosis
#6	AnnotatorNotes T8	C0026987; Myelofibrosis; Neoplastic Process
T9	DISO 559 572	Mielofibrosis
#7	AnnotatorNotes T9	C0026987; Myelofibrosis; Neoplastic Process
T10	PROC 651 662	Diagnóstico
#8	AnnotatorNotes T10	C0011900; Diagnosis; Diagnostic Procedure
T11	ANAT 907 911	bazo
#9	AnnotatorNotes T11	C0037993; Spleen; Body Part, Organ, or Organ Component | C1278932; Entire spleen; Body Part, Organ, or Organ Component
T12	DISO 677 679	MF
#10	AnnotatorNotes T12	C0026987; Myelofibrosis; Neoplastic Process
T13	DISO 684 707	fibrosis de médula ósea
#11	AnnotatorNotes T13	C2355575; bone marrow fibrosis; Finding
T14	ANAT 696 707	médula ósea
#12	AnnotatorNotes T14	C0005953; Bone Marrow; Tissue
T15	ANAT 888 892	bazo
#13	AnnotatorNotes T15	C0037993; Spleen; Body Part, Organ, or Organ Component | C1278932; Entire spleen; Body Part, Organ, or Organ Component
T16	ANAT 938 961	margen costal izquierdo
T17	DISO 1063 1070	síntoma
#14	AnnotatorNotes T17	C1457887; Symptoms; Sign or Symptom
T18	PROC 1129 1140	tratamiento
#15	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	CHEM 1152 1163	ruxolitinib
#16	AnnotatorNotes T19	C2931926; ruxolitinib; Organic Chemical · Pharmacologic Substance
T20	CHEM 1172 1187	inhibidores JAK
T21	PROC 70 103	investiga la eficacia y seguridad
T22	ANAT 991 1000	esplénica
#17	AnnotatorNotes T22	C0037993; Spleen; Body Part, Organ, or Organ Component | C1278932; Entire spleen; Body Part, Organ, or Organ Component
T23	DISO 163 185	mutaciones moleculares
T24	DISO 407 429	mutaciones moleculares
T25	DISO 495 517	mutaciones moleculares
T26	DISO 586 608	mutaciones moleculares
T27	DISO 804 812	mutación
T28	DISO 752 769	estado mutacional
T29	Date 13 17	2014
T30	LIVB 122 131	pacientes
#18	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	LIVB 366 375	pacientes
#19	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group
T32	LIVB 777 786	Pacientes
#20	AnnotatorNotes T32	C0030705; Patients; Patient or Disabled Group
T33	GENE 833 842	genes HMR
#21	AnnotatorNotes T33	C1367453; NR4A1 gene; Gene or Genome
T34	LIVB 874 883	Pacientes
#22	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T36	LIVB 1002 1011	Pacientes
#23	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	LIVB 1115 1124	Pacientes
#24	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	GENE 770 774	JAK2
#25	AnnotatorNotes T38	C1334291; JAK2 gene; Gene or Genome
T39	GENE 844 849	ASXL1
#26	AnnotatorNotes T39	C1425445; ASXL1 gene; Gene or Genome
T40	GENE 851 855	EZH2
#27	AnnotatorNotes T40	C1333368; EZH2 gene; Gene or Genome
T41	GENE 857 862	SRSF2
#28	AnnotatorNotes T41	C1419992; SRSF2 gene; Gene or Genome
T42	GENE 865 871	IDH1/2
#29	AnnotatorNotes T42	C5426663; IDH1 gene & IDH2 gene; Gene or Genome
A1	Status T18 History_of
A2	Status T19 History_of
A3	Status T20 History_of
#30	AnnotatorNotes T21	C0511730; Identify product efficacy and safety issues; Health Care Activity
#31	AnnotatorNotes T5	C0511730; Identify product efficacy and safety issues; Health Care Activity
#32	AnnotatorNotes T4	C0282461; Phase 3 Clinical Trials; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product + C1096776; Multicenter Study; Research Activity
#33	AnnotatorNotes T16	C0502461; Left costal margin; Body Location or Region
#34	AnnotatorNotes T20	C3854325; Janus kinase inhibitor; Pharmacologic Substance
T35	Neg_cue 893 895	no
T43	Quantifier_or_Qualifier 896 904	palpable
A4	Assertion T43 Negated
#35	AnnotatorNotes T43	C0522499; Palpable; Qualitative Concept
T44	Quantifier_or_Qualifier 912 920	palpable
#36	AnnotatorNotes T44	C0522499; Palpable; Qualitative Concept
R1	Experiences Arg1:T30 Arg2:T2	
R2	Experiences Arg1:T30 Arg2:T3	
R3	Overlap Arg1:T3 Arg2:T23	
T45	Quantifier_or_Qualifier 150 158	temprana
#37	AnnotatorNotes T45	C1279919; Early; Temporal Concep
R4	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T45	
T46	Quantifier_or_Qualifier 394 402	temprana
#38	AnnotatorNotes T46	C1279919; Early; Temporal Concept
R5	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T46	
T47	Quantifier_or_Qualifier 482 490	temprana
#39	AnnotatorNotes T47	C1279919; Early; Temporal Concept
R6	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T47	
T48	Quantifier_or_Qualifier 573 581	temprana
#40	AnnotatorNotes T48	C1279919; Early; Temporal Concept
R7	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T48	
T49	Observation 189 200	alto riesgo
#41	AnnotatorNotes T49	C4319571; High risk; Finding
R8	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T49	
T50	Observation 433 444	alto riesgo
#42	AnnotatorNotes T50	C4319571; High risk; Finding
R9	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T50	
T51	Observation 521 532	alto riesgo
#43	AnnotatorNotes T51	C4319571; High risk; Finding
R10	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T51	
T52	Observation 612 623	alto riesgo
#44	AnnotatorNotes T52	C4319571; High risk; Finding
R11	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T52	
R12	Overlap Arg1:T9 Arg2:T26	
R13	Overlap Arg1:T8 Arg2:T25	
R14	Experiences Arg1:T30 Arg2:T23	
R15	Experiences Arg1:T30 Arg2:T49	
R16	Experiences Arg1:T31 Arg2:T6	
R17	Experiences Arg1:T31 Arg2:T7	
R18	Experiences Arg1:T31 Arg2:T24	
R19	Overlap Arg1:T7 Arg2:T24	
R20	Experiences Arg1:T31 Arg2:T50	
R21	Location_of Arg1:T14 Arg2:T13	
R22	Overlap Arg1:T12 Arg2:T13	
T53	Quantifier_or_Qualifier 711 727	al menos Grado 1
R23	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T53	
R24	Overlap Arg1:T12 Arg2:T28	
R25	Overlap Arg1:T13 Arg2:T28	
R26	Location_of Arg1:T38 Arg2:T28	
R27	Experiences Arg1:T32 Arg2:T27	
T54	Quantifier_or_Qualifier 791 803	al menos una
R28	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T54	
#45	AnnotatorNotes T27	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
R29	Location_of Arg1:T33 Arg2:T27	
R30	Location_of Arg1:T39 Arg2:T27	
R31	Location_of Arg1:T40 Arg2:T27	
R32	Location_of Arg1:T41 Arg2:T27	
R33	Location_of Arg1:T42 Arg2:T27	
R34	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T43	
R35	Negation Arg1:T35 Arg2:T43	
R36	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T44	
T55	Result_or_Value 921 928	</=5 cm
R37	Has_Result_or_Value Arg1:T11 Arg2:T55	
R38	Used_for Arg1:T19 Arg2:T18	
R39	Used_for Arg1:T20 Arg2:T18	
R40	Experiences Arg1:T37 Arg2:T18	
T56	CONC 1027 1031	MF-7
#46	AnnotatorNotes T56	[Myelofibrosis 7-item symptom scale]
T57	Result_or_Value 1032 1038	</= 15
R41	Has_Result_or_Value Arg1:T56 Arg2:T57	
R42	Experiences Arg1:T36 Arg2:T17	
T58	Observation 1044 1070	puntuación de cada síntoma
#47	AnnotatorNotes T58	C3476546; Symptoms score; Finding
T59	Result_or_Value 1082 1087	</= 3
R43	Has_Result_or_Value Arg1:T58 Arg2:T59	
R45	Overlap Arg1:T58 Arg2:T17	
T60	Observation 907 920	bazo palpable
#48	AnnotatorNotes T60	C0241228; Spleen palpable; Finding
R46	Experiences Arg1:T34 Arg2:T60	
R47	Location_of Arg1:T16 Arg2:T60	
T61	CONC 965 1000	punto de mayor protrusión esplénica
R48	Location_of Arg1:T61 Arg2:T60	
T62	Observation 888 904	bazo no palpable
#49	AnnotatorNotes T62	C0426697; Spleen not palpable; Finding
R49	Experiences Arg1:T34 Arg2:T62	
A5	Experiencer T30 Patient
A6	Experiencer T31 Patient
A7	Experiencer T32 Patient
A8	Experiencer T34 Patient
A9	Experiencer T36 Patient
A10	Experiencer T37 Patient
